Batu Chooses Unusual Path, Unusual Weapon

Crowdfunding Part of Financial Strategy; Cancer Fight Aims to Cut Tumors’ Blood Supply

When it comes to small and scrappy biotechs, Batu Biologics might take the cake. Led by a 25-year-old college dropout, Batu got its start with a $100,000 infusion of cash from a crowdfunding campaign the team launched online… the company has filed 29 patents, raised over $2 million, and is gearing up to start testing its anti-cancer vaccine in humans.

Download full article here

Startup applies to test cancer therapy

Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors.

The San Diego startup said Thursday that its therapy, ValloVax™, will be tested in a Phase 1/2 trial against non-small cell lung cancer once the U.S. Food and Drug Administration approves the application.

ValloVax™ targets proteins found in blood vessels induced by cancer that are not present in ordinary blood vessels. In mouse models, the vaccine inhibited tumor formation in melanoma, breast and lung cancer.

UCSD brain cancer specialist Dr. Santosh Kesari said he’s asked Batu if he can take part in the clinical trial.

“The innovative thing about this technology is that you’re combining two powerful, validated technologies in one: angiogenesis inhibitors and immunotherapy,” Kesari said. “I think it has a lot of potential.”

Read the full article as posted by U-T San Diego here

Bringing Innovative Weapons To the Cancer Battlefront

What if we could engineer “killer cells” to wage war on tumors, and then program the little soldiers to seek a specific kill zone? What if glowing tumors could tell doctors which tissue material to remove during surgery?

These are just two of the recent breakthroughs in cancer research being undertaken by the hundreds of local bio- tech firms that are pumping money and resources into the oncology market — a market that’s booming with players, inno- vations and a demand that just won’t quit.

San Diego-based Batu Biologics Inc., is taking a more inventive approach. Batu’s new cancer vaccine, ValloVax™, is designed to target and kill blood vessels that feed tumor growth. In doing so, Batu expects white blood cells to invade the tumor site and encourage immune-based remission. Without being able to form new blood vessels, a tumor cannot grow bigger than 1 millimeter, said 22-year-old CEO Samuel Wagner.

Wagner said the company is set to file an investigational new drug application with the U.S. Food and Drug Admin- istration in the first quarter of 2015, and hopes to begin clinical trials after approval. Batu recently signed a license agreement with the Regents of the University of California granting Batu exclusive rights to develop and commercialize their HMGB-1 derived vaccine platform, a technology that can be used in conjunction with ValloVax™ to “supercharge” the potency of the immune response.

Download the full article as seen in the San Diego Business Journal here

Startup Conducts Unusual Funding ‘Experiment’

A local biotech startup and its 22 year old CEO — with support of local industry veterans — are trying a no-strings-attached funding model to finance their research on a potential cancer vaccine.

“If we raise money at this point in the preclinical stages, the venture capitalists or investors are going to take a large portion of our shares,” President and CEO Samuel Wagner said. “If we want to have the biggest payout for the founders, it’s really in our benefit to raise the least amount of capital in the early stages of the company.”

Batu’s new cancer vaccine is designed to target and kill blood vessels that feed tumor growth. In doing so, Batu expects white blood cells to invade the tumor site and encourage immune-based remission. Without being able to form new blood vessels, a tumor cannot grow bigger than about 1 millimeter, Wagner said, adding that tumors need those blood vessels to become malignant. “Everybody has been attacking the tumor directly,” Wagner said. “We’re choosing a different approach. … We’re trying to choke it of this blood supply.”

Download the full article as seen in the San Diego Business Journal here

Anti-angiogenic cancer vaccinations – a promising future for cancer immunotherapy

In this video, Samuel C. Wagner, President and CEO of Batu Biologics, discusses Facciponte’s study of a TEM-1 DNA vaccination’s efficacy as a cancer therapeutic and the affect of the vaccination on healthy angiogenesis processes in the body.

[video_left][video_frame]
[iframe url=”http://www.youtube.com/embed/IK7LDuxUUJo” width=”572″ height=”312″]
[/video_frame]

Watch the video

Awarded Exclusive License from UC San Diego

Batu Biologics Awarded Exclusive License from University of California San Diego for Drug That Stimulates Immune System to Kill Cancer
Biotech Start Up Expands its Oncology Immunotherapeutic Product Pipeline

Productive and beneficial relationships with cutting-edge pharmaceutical companies such as Batu Biologics help speed further development of promising new drugs to those most in need.

Read the full article at businesswire.com

Batu Biologics Names Chief Scientific Officer

Batu Biologics Names Business Development and R&D Expert as Chief Scientific Officer
International Biotech Market Expert Will Help Boost Company’s Business Strategy

Her impeccable clinical trials expertise, combined with stellar interpersonal skills and keen knowledge of international markets, will serve the company well in its quest to be the first to successfully launch an anti-angiogenic lung cancer vaccine on the market.

Read the full article at businesswire.com

Achieves Goal in Successful Crowdfunding Campaign

Batu Biologics Achieves Goal in Successful Crowdfunding Campaign
Biotech Startup Aims for FDA Approval for Novel Anti-Angiogenic Cancer Vaccine

Using a fundraising approach seldom seen in the life sciences sector, Batu Biologics, an immunotherapy company working to develop the first anti-angiogenic cancer vaccine, has successfully raised $100,000 through the Indiegogo crowdfunding platform.

Read the full article at businesswire.com

Lung Cancer Immunotherapy Featured in CEOCFO Magazine

Batu Biologics’ Lung Cancer Immunotherapy Featured in CEOCFO Magazine
Anti-Angiogenesis Lung Cancer Vaccine Discussed as Potential “Next Generation” Non-Toxic Therapy

Given that the majority of lung cancers are diagnosed late in progression, the majority of patients have limited treatment options, which often carry a heavy burden of toxicity.

Read the full article at businesswire.com